Publication: Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study.
dc.contributor.author | Domingo, Pere | |
dc.contributor.author | Suarez-Lozano, Ignacio | |
dc.contributor.author | Gutierrez, Félix | |
dc.contributor.author | Estrada, Vicente | |
dc.contributor.author | Knobel, Hernando | |
dc.contributor.author | Palacios, Rosario | |
dc.contributor.author | Antela, Antonio | |
dc.contributor.author | Blanco, José-Ramón | |
dc.contributor.author | Fulladosa, Xavier | |
dc.contributor.author | VACH | |
dc.date.accessioned | 2023-01-25T13:32:57Z | |
dc.date.available | 2023-01-25T13:32:57Z | |
dc.date.issued | 2019-04-24 | |
dc.description.abstract | The use of combination antiretroviral therapy has led to dramatic improvements in the life expectancy of HIV-infected persons. As result, the HIV population is aging and increasingly facing illnesses typically seen in the elderly, such as chronic kidney disease (CKD). A retrospective longitudinal study was conducted using data from years 2010 and 2014 in all HIV-infected persons enrolled at the Spanish VACH cohort. We analyzed the prevalence and the predictive factors for developing CKD (estimated glomerular filtration rate, eGFR The CKD prevalence at baseline was 456/8968, 5.1% [4.6-5.6%]. Of 8512 HIV-positive individuals examined without CKD at baseline (73.7% male, median age 44 years-old), 2.15% developed CKD (eGFR The prevalence and risk factors for CKD and its progression are high in the VACH cohort. Thus, preventive measures such as control of hypertension, diabetes and obesity, as well as efforts for avoiding exposure to nephrotoxic drugs, including some antiretrovirals, are warranted in this aging HIV population. | |
dc.identifier.doi | 10.1016/j.nefro.2019.01.009 | |
dc.identifier.essn | 2013-2514 | |
dc.identifier.pmid | 31027896 | |
dc.identifier.unpaywallURL | https://doi.org/10.1016/j.nefro.2019.01.009 | |
dc.identifier.uri | http://hdl.handle.net/10668/13882 | |
dc.issue.number | 5 | |
dc.journal.title | Nefrologia | |
dc.journal.titleabbreviation | Nefrologia (Engl Ed) | |
dc.language.iso | en | |
dc.language.iso | es | |
dc.organization | Hospital Infanta Elena | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.page.number | 497-505 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Ageing | |
dc.subject | Diabetes | |
dc.subject | Disfunción renal | |
dc.subject | Envejecimiento | |
dc.subject | España | |
dc.subject | Fumarato de disoproxilo de tenofovir | |
dc.subject | Hipertensión | |
dc.subject | Human immunodeficiency virus | |
dc.subject | Hypertension | |
dc.subject | Insuficiencia renal | |
dc.subject | Renal impairment | |
dc.subject | Renal insufficiency | |
dc.subject | Spain | |
dc.subject | Tenofovir | |
dc.subject | Tenofovir disoproxil fumarate | |
dc.subject | Virus de la inmunodeficiencia humana | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Age Factors | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Anti-HIV Agents | |
dc.subject.mesh | Cross-Sectional Studies | |
dc.subject.mesh | Female | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Glomerular Filtration Rate | |
dc.subject.mesh | HIV Infections | |
dc.subject.mesh | HIV Long-Term Survivors | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Longitudinal Studies | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Prevalence | |
dc.subject.mesh | Renal Insufficiency, Chronic | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Spain | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Young Adult | |
dc.title | Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 39 | |
dspace.entity.type | Publication |